English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/207542
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: Current approaches and challenges

AuthorsGuadix, Juan Antonio; López-Beas, Javier; Clares Naveros, Beatriz; Soriano-Ruiz, José Luis; Zugaza, José L.; Gálvez Martín, Patricia
KeywordsMesenchymal stem cells
Good manufacturing practice
Cell characterization
Release criteria and manufacturing process
Issue Date24-Oct-2019
PublisherMolecular Diversity Preservation International
CitationPharmaceutics 11(11): 502 (2019)
AbstractHuman Mesenchymal Stem Cells (hMSCs) play an important role as new therapeutic alternatives in advanced therapies and regenerative medicine thanks to their regenerative and immunomodulatory properties, and ability to migrate to the exact area of injury. These properties have made hMSCs one of the more promising cellular active substances at present, particularly in terms of the development of new and innovative hMSC-based products. Currently, numerous clinical trials are being conducted to evaluate the therapeutic activity of hMSC-based products on specific targets. Given the rapidly growing number of hMSC clinical trials in recent years and the complexity of these products due to their cellular component characteristics and medicinal product status, there is a greater need to define more stringent, specific, and harmonized requirements to characterize the quality of the hMSCs and enhance the analysis of their safety and efficacy in final products to be administered to patients. These requirements should be implemented throughout the manufacturing process to guarantee the function and integrity of hMSCs and to ensure that the hMSC-based final product consistently meets its specifications across batches. This paper describes the principal phases involved in the design of the manufacturing process and updates the specific technical requirements needed to address the appropriate clinical use of hMSC-based products. The challenges and limitations to evaluating the safety, efficacy, and quality of hMSCs have been also reviewed and discussed.
Publisher version (URL)http://dx.doi.org/10.3390/pharmaceutics11110552
Identifiersdoi: 10.3390/pharmaceutics11110552
issn: 1999-4923
e-issn: 1999-4923
Appears in Collections:(CABIMER) Artículos
Files in This Item:
File Description SizeFormat 
pharmaceutics-11-00552.pdf1,59 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.